GlassScriptPhysician profile
Jayasree Jonnadula
NPI 1578946323
$3,294.84
in general payments reported to CMS, 2019-2025
26 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $166 · 2022: $454 · 2023: $1,854 · 2024: $495 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Travel and Lodging: $1,073 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.08 |
| Travel and Lodging | $1,073.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,449.02 | 2021-2025 | Minimed 780g |
| Novo Nordisk INC | $388.18 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $150.06 | 2022-2024 | |
| Amgen INC. | $138.34 | 2022-2024 | Repatha, Otezla, Evenity |
| Medtronic Minimed, INC. | $135.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $126.60 | 2022-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $111.80 | 2023-2025 | Korlym |
| Amarin Pharma, INC. | $108.44 | 2021-2022 | |
| Lilly USA, LLC | $86.36 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $79.28 | 2021-2022 | |
| Insulet Corporation | $73.15 | 2022-2024 | Omnipod |
| Dexcom, INC. | $62.38 | 2021-2023 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $52.24 | 2024 | Ilet Bionic Pancreas |
| Ibsa Pharma INC. | $50.71 | 2023-2024 | Licart, Tirosint, Tirosint |
| Grifols USA, LLC | $45.48 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31.80 | 2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Paratek Pharmaceuticals, INC. | $31.41 | 2022-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.60 | 2023 | Jardiance |
| Globus Medical, INC. | $26.99 | 2025 | Senza |
| Tandem Diabetes Care, INC. | $23.14 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Biohaven Pharmaceutical Holding Company LTD. | $17.44 | 2022 | |
| Exact Sciences Corporation | $17.19 | 2024 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $16.32 | 2024 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $15.57 | 2021 | |
| Horizon Therapeutics Plc | $14.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayasree Jonnadula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.